NASDAQ · RNA
Healthcare · Biotechnology
$11.35
Down-$2.84 (-20.01%)
Updated Sep 9, 2026, 8:48 AM
SID Score
4.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RNA closed at $11.35 after 20 trading sessions, down 7.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $14.08 | $14.19 | $10.75 | $11.35 | 1.72M |
| Sep 4, 2026 | $14.51 | $14.65 | $14.01 | $14.19 | 167.79K |
| Sep 3, 2026 | $14.19 | $14.68 | $13.99 | $14.60 | 164.91K |
| Sep 2, 2026 | $13.77 | $14.098 | $13.76 | $14.06 | 111.64K |
| Sep 1, 2026 | $13.24 | $13.92 | $13.20 | $13.77 | 178.71K |
| Aug 31, 2026 | $13.53 | $13.55 | $13.10 | $13.32 | 97.05K |
| Aug 28, 2026 | $13.87 | $13.9508 | $13.51 | $13.64 | 108.64K |
| Aug 27, 2026 | $13.78 | $14.09 | $13.5916 | $13.98 | 120.56K |
| Aug 26, 2026 | $13.93 | $14.07 | $13.66 | $13.85 | 179.35K |
| Aug 25, 2026 | $13.72 | $14.05 | $13.41 | $14.00 | 166.58K |
| Aug 24, 2026 | $13.27 | $13.635 | $13.04 | $13.62 | 140.56K |
| Aug 21, 2026 | $13.53 | $13.59 | $12.96 | $13.20 | 180.68K |
| Aug 20, 2026 | $13.75 | $13.875 | $13.20 | $13.48 | 218.81K |
| Aug 19, 2026 | $13.00 | $13.72 | $12.85 | $13.71 | 360.32K |
| Aug 18, 2026 | $12.91 | $12.96 | $12.72 | $12.84 | 107.92K |
| Aug 17, 2026 | $12.78 | $13.345 | $12.78 | $12.96 | 212.55K |
| Aug 14, 2026 | $12.21 | $12.97 | $12.08 | $12.84 | 176.08K |
| Aug 13, 2026 | $12.21 | $12.46 | $12.0301 | $12.33 | 127.14K |
| Aug 12, 2026 | $12.27 | $12.35 | $12.06 | $12.17 | 84.17K |
| Aug 11, 2026 | $12.25 | $12.44 | $12.195 | $12.27 | 84.25K |
The latest Smart Investors Daily articles mentioning RNA.
RNA research
Company profile and research snapshot.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Leerink Partners | Outperform | — |
| Mar 11, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September.
Yahoo · Aug 28, 2026
On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to […]
Benzinga · Aug 14, 2026
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.
Benzinga · Aug 13, 2026
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of $(1.21) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNA.
